uniQure N.V. Increase (Decrease) in Contract with Customer, Liability
uniQure N.V. (QURE) reported Increase (Decrease) in Contract with Customer, Liability of -$33.64 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-02-27
- uniQure N.V. increase (decrease) in contract with customer, liability for the quarter ending 2020-12-31 was -$31.56M.
- uniQure N.V. increase (decrease) in contract with customer, liability for the quarter ending 2020-09-30 was -$482.00K.
- uniQure N.V. increase (decrease) in contract with customer, liability for the quarter ending 2020-06-30 was -$1.87M.
- uniQure N.V. increase (decrease) in contract with customer, liability for the quarter ending 2020-03-31 was $270.00K.
- uniQure N.V. increase (decrease) in contract with customer, liability for fiscal 2020 was -$33.64M.
- uniQure N.V. increase (decrease) in contract with customer, liability for fiscal 2019 was -$5.00M.
- uniQure N.V. increase (decrease) in contract with customer, liability for fiscal 2018 was -$8.46M.
- uniQure N.V. increase (decrease) in contract with customer, liability for fiscal 2017 was -$21.08M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$31.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$32.04M derived: sum of 2 quarters · filed 2023-02-27 | -$33.91M derived: sum of 3 quarters · filed 2023-02-27 | -$33.64M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | -$2.35M derived: sum of 2 quarters · filed 2020-10-27 | -$2.08M 10-Q · filed 2020-10-27 | -$3.68M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$1.60M 10-Q · filed 2020-07-30 | -$3.20M derived: sum of 3 quarters · filed 2022-02-25 | -$3.92M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $270.00K 10-Q · filed 2021-05-10 | -$1.33M derived: sum of 2 quarters · filed 2022-02-25 | -$2.05M derived: sum of 3 quarters · filed 2022-02-25 | -$4.19M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$2.32M derived: sum of 2 quarters · filed 2022-02-25 | -$4.46M derived: sum of 3 quarters · filed 2022-02-25 | -$5.00M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$720.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | -$2.87M derived: sum of 2 quarters · filed 2020-10-27 | -$3.40M 10-Q · filed 2020-10-27 | -$4.72M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$2.68M 10-Q · filed 2020-07-30 | -$4.00M derived: sum of 3 quarters · filed 2021-03-01 | -$6.57M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$537.00K 10-Q · filed 2020-04-29 | -$1.86M derived: sum of 2 quarters · filed 2021-03-01 | -$4.42M derived: sum of 3 quarters · filed 2021-03-01 | -$6.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$3.88M derived: sum of 2 quarters · filed 2021-03-01 | -$5.90M derived: sum of 3 quarters · filed 2021-03-01 | -$8.46M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | -$4.58M derived: sum of 2 quarters · filed 2019-10-28 | -$7.14M 10-Q · filed 2019-10-28 | |
| 2018-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$4.58M 10-Q · filed 2019-07-29 | ||
| 2018-03-31 | -$2.56M 10-Q · filed 2019-04-29 | |||
| 2017-12-31 | -$21.08M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | -$5.70M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |